Review: Immunomodulators for all patients with inflammatory bowel disease?
Recent insight into the pathogenesis of Crohn’s disease (CD) and ulcerative colitis (UC) have led to the development of new treatment options, with a progressive shift to more evidence-based strategies based on sound pathophysiological rationales. A better understanding of inflammatory bowel disease...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2010-01-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/1756283X09354136 |
| _version_ | 1811222371060678656 |
|---|---|
| author | Sandro Ardizzone Andrea Cassinotti Gianpiero Manes Gabriele Bianchi Porro |
| author_facet | Sandro Ardizzone Andrea Cassinotti Gianpiero Manes Gabriele Bianchi Porro |
| author_sort | Sandro Ardizzone |
| collection | DOAJ |
| description | Recent insight into the pathogenesis of Crohn’s disease (CD) and ulcerative colitis (UC) have led to the development of new treatment options, with a progressive shift to more evidence-based strategies based on sound pathophysiological rationales. A better understanding of inflammatory bowel disease (IBD) pathophysiology has progressively resulted in a more frequent use of immunomodulators. We review the recommended or suggested use of conventional immunomodulators such as azathioprine, 6-mercaptopurine, methotrexate in the treatment of IBD. Moreover, an effort is made to explore some critical areas in which early and more diffuse use of these agents may be advocated. |
| first_indexed | 2024-04-12T08:15:49Z |
| format | Article |
| id | doaj.art-a338e820925649d8952743216ba9d90c |
| institution | Directory Open Access Journal |
| issn | 1756-283X |
| language | English |
| last_indexed | 2024-04-12T08:15:49Z |
| publishDate | 2010-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-a338e820925649d8952743216ba9d90c2022-12-22T03:40:49ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X2010-01-01310.1177/1756283X09354136Review: Immunomodulators for all patients with inflammatory bowel disease?Sandro ArdizzoneAndrea CassinottiGianpiero ManesGabriele Bianchi PorroRecent insight into the pathogenesis of Crohn’s disease (CD) and ulcerative colitis (UC) have led to the development of new treatment options, with a progressive shift to more evidence-based strategies based on sound pathophysiological rationales. A better understanding of inflammatory bowel disease (IBD) pathophysiology has progressively resulted in a more frequent use of immunomodulators. We review the recommended or suggested use of conventional immunomodulators such as azathioprine, 6-mercaptopurine, methotrexate in the treatment of IBD. Moreover, an effort is made to explore some critical areas in which early and more diffuse use of these agents may be advocated.https://doi.org/10.1177/1756283X09354136 |
| spellingShingle | Sandro Ardizzone Andrea Cassinotti Gianpiero Manes Gabriele Bianchi Porro Review: Immunomodulators for all patients with inflammatory bowel disease? Therapeutic Advances in Gastroenterology |
| title | Review: Immunomodulators for all patients with inflammatory bowel disease? |
| title_full | Review: Immunomodulators for all patients with inflammatory bowel disease? |
| title_fullStr | Review: Immunomodulators for all patients with inflammatory bowel disease? |
| title_full_unstemmed | Review: Immunomodulators for all patients with inflammatory bowel disease? |
| title_short | Review: Immunomodulators for all patients with inflammatory bowel disease? |
| title_sort | review immunomodulators for all patients with inflammatory bowel disease |
| url | https://doi.org/10.1177/1756283X09354136 |
| work_keys_str_mv | AT sandroardizzone reviewimmunomodulatorsforallpatientswithinflammatoryboweldisease AT andreacassinotti reviewimmunomodulatorsforallpatientswithinflammatoryboweldisease AT gianpieromanes reviewimmunomodulatorsforallpatientswithinflammatoryboweldisease AT gabrielebianchiporro reviewimmunomodulatorsforallpatientswithinflammatoryboweldisease |